Ascites Predicts Treatment Benefit of Bevacizumab in Front-Line Therapy of Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers: An NRG Oncology/Gog Study

Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2015.07.103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Gynecologic Oncology
GynecologyOncologyObstetrics
2013English

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation

JAMA - Journal of the American Medical Association
Medicine
2006English

The Prognostic Value of Morphometry in Advanced Epithelial Ovarian Cancers

British Journal of Cancer
Cancer ResearchOncology
1995English

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Lancet Oncology
Oncology
2011English

Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications

Archives of Gynecology and Obstetrics
MedicineGynecologyObstetrics
2016English

Ovarian Cancer May Originate in the Fallopian Tube

Cancer Discovery
Oncology
2012English

Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation

Current Oncology
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy